OptimizeRx (NASDAQ:OPRX) Receives Market Outperform Rating from JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a research note issued to investors on Thursday,Benzinga reports. JMP Securities currently has a $8.00 price objective on the stock.

A number of other equities research analysts have also commented on OPRX. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 price objective (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Stephens initiated coverage on shares of OptimizeRx in a research report on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target on the stock. Lake Street Capital reiterated a “buy” rating and set a $11.00 price target on shares of OptimizeRx in a report on Tuesday, December 24th. B. Riley dropped their price objective on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Finally, Roth Mkm reaffirmed a “buy” rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Trading Down 2.8 %

NASDAQ OPRX opened at $5.51 on Thursday. The business’s 50-day moving average price is $5.24 and its two-hundred day moving average price is $6.58. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $16.65. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insider Buying and Selling

In other OptimizeRx news, CEO William J. Febbo bought 20,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the acquisition, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. The trade was a 3.44 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Rice Hall James & Associates LLC increased its position in shares of OptimizeRx by 24.0% during the third quarter. Rice Hall James & Associates LLC now owns 615,441 shares of the company’s stock valued at $4,751,000 after acquiring an additional 119,306 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of OptimizeRx by 12.5% in the second quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock worth $3,241,000 after purchasing an additional 35,957 shares during the last quarter. Essex Investment Management Co. LLC increased its holdings in shares of OptimizeRx by 42.9% in the 3rd quarter. Essex Investment Management Co. LLC now owns 242,025 shares of the company’s stock worth $1,868,000 after buying an additional 72,672 shares during the last quarter. Bullseye Asset Management LLC increased its stake in OptimizeRx by 55.6% in the third quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after acquiring an additional 76,458 shares during the last quarter. Finally, AMH Equity Ltd increased its position in shares of OptimizeRx by 25.0% during the 4th quarter. AMH Equity Ltd now owns 125,000 shares of the company’s stock valued at $608,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.